29th August 2019 – The global polycystic
ovarian syndrome (PCOS) treatment market size is expected to value at
USD 5.1 billion by 2025. The market is subject to witness a substantial growth
due to the easy identification of symptoms associated with this syndrome, and
easy accessibility to a range of drug essential for the treatment. Furthermore,
substantial focus on the development of the drug to find permeant solution
involving complete cure for the polycystic ovarian syndrome (PCOS) and rising
investment by industry players for research development of drugs are some of
the critical factors expected to fuel growth of the PCOS treatment market
during the forecast period. Globally, the market is predicted to grow at CAGR
of 5.0% in forecast period, providing numerous opportunity for market players
to invest for research and development in the polycystic ovarian syndrome
(PCOS) treatment market.
Currently, no particular medication has
been developed for treatment of PCOS treatment market. Thus, symptoms diagnosis
is the prime aim for healthcare professionals. The signs of the polycystic
ovarian syndrome (PCOS) are varied and needs treatment by using a range of drug
and their combination. Several efforts have been made by industry leader for
the development of the particular drug and therapy to treat the root cause of
the polycystic ovarian syndrome (PCOS).
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/polycystic-ovarian-syndrome-pcos-treatment-market/request-sample
In some cases, involving inefficient
drug therapy, surgery is highly recommended by healthcare professional for
treatment. Commonly implemented surgeries for treatment of the polycystic
ovarian syndrome (PCOS) are ovarian wedge resection and laparoscopic drilling
of ovaries. Other types of the surgeries such as oophorectomy, hysterectomy,
and cyst aspiration are proved vital for treatment, thus positively influencing
growth of the market in recent years.
Polycystic ovarian syndrome (PCOS)
therapy majorly involves lifestyle changes and food patterns consisting of a
well-balanced diet, regular exercise, and medicines like that of oral
contraceptives, insulin sensitizing agents, and anti-depressants. Insulin
sensitizing agents market segment is one of the fastest growing due to its
critical uses. Medicines consisting of essential elements such as Glucophage XR
(Metformin) and other products consisting of Troglitazone, Rosiglitazone, and
Pioglitazone are utilized in large scale. Conditions that involve polycystic
ovarian syndrome (PCOS), the metabolic dysfunction causes additional of
secretion androgen that directly affects insulin secretion leading to higher
risk diabetes. The use of insulin-sensitizing agents plays a vital role for
therapeutics to achieve lower insulin levels, lowers the production of
androgen, and balances the hormone levels.
Polycystic ovary syndrome (PCOS) are
more prevalent among pregnant women’s by affecting hormone levels. Women
suffering from Polycystic ovary syndrome (PCOS) produces high content of male
hormones causing excess amount hair growth on the face and body. Polycystic
ovary syndrome (PCOS) also contributes to long-lasting health issues such as
diabetes and heart disease. Though, use of birth control pills and diabetes
drugs is prescribed amount helps to fix the hormone imbalance and reducing
symptoms.
The polycystic ovarian syndrome (PCOS)
treatment market is divided into regional market segment such as North America,
Europe, Asia-Pacific, Latin America and Africa. North America has shown major
growth in recent years owing to increasing incidence related to obesity and
overweight, adoption of latest methodologies for treatment of PCOS and existence
well-established healthcare infrastructure.
As per various report suggest
approximately as many as seven percent of women are affected by polycystic
ovary syndrome (PCOS) in the North America region only. Asia-Pacific region is
predicted to hold major market share in the polycystic ovarian syndrome (PCOS)
treatment market with massive growth in forecast period. Countries such as
India, China and Singapore are leading the Asia-Pacific market with increasing
number of patients pool and rising investment by industry players considering
potential opportunities in the region.
The key players in the polycystic
ovarian syndrome (PCOS) treatment industry are AstraZeneca Plc, Bayer AG, Merck
Group, Abbott Laboratories, Sanofi S.A, Pfizer Incorporations, Bristol-Myer
Squibb Company, and Novartis AG.
For More Details, Visit @ http://www.millioninsights.com
No comments:
Post a Comment